Fig. 4.

Anti-PD-1 increases tumor infiltration with antigen-specific CD8α⁺ T cells. Mice were implanted with C3 tumors and treated with 1 week of mCPA commencing 14 days after implantation. Mice were vaccinated on study day 21 and treated with anti-PD-1 or isotype control on study day 26. All mice were terminated on study day 31. a Percent tumor infiltrating leukocytes (TIL) defined as % CD45 positive cells; b Percent CD8α positive T cells in the TIL population; c Percent R9F-specific CD8α T cells in the TIL population. Results pooled from two separate experiments, n = 4–8, statistics by 1-way ANOVA with LSD post-test, *p < 0.05, **p < 0.01; ns: not significant (p > 0.05)